☆ 4.2 Review

St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer - A Brief Summary of the Consensus Discussion

BREAST CARE (2023)

Related references

Note: Only part of the references are listed.

Article Genetics & Heredity

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+HER2-BC)

Lorenzo Ferrando et al.

Summary: Breast cancer is the most common cancer in women and is often treated with endocrine therapy. However, many patients develop resistance to this therapy, leading to tumor recurrence. In this study, researchers analyzed the molecular characteristics of hormone receptor positive breast cancer patients and identified potential mechanisms of endocrine resistance, including amplification of the ESR1 gene and mutations in MAP3K. Patients with MAP3K mutations had a worse prognosis.

PLOS GENETICS (2023)

Add to Collection

Article Oncology

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer

S. M. Buijs et al.

Summary: This study found that dose reduction of tamoxifen based on endoxifen levels can decrease its side-effects and improve patients' quality of life.

ESMO OPEN (2023)

Add to Collection

Article Nutrition & Dietetics

Only virgin type of olive oil consumption reduces the risk of mortality. Results from a Mediterranean population-based cohort

Carolina Donat-Vargas et al.

Summary: The study found that moderate daily consumption of virgin olive oil is associated with a lower risk of all-cause and cardiovascular mortality, while common olive oil does not show the same effect.

EUROPEAN JOURNAL OF CLINICAL NUTRITION (2023)

Add to Collection

Review Oncology

Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis

Nerea Becerra-Tomas et al.

Summary: Little is known about the impact of diet on breast cancer prognosis. Systematic reviews and meta-analyses were conducted to summarize the evidence on postdiagnosis dietary factors and breast cancer outcomes from randomized controlled trials and observational studies. A total of 108 publications were identified, and the results generally showed limited or no significant associations between diet and breast cancer outcomes, except for some suggestive evidence related to dietary patterns, isoflavone intake, dietary fiber intake, and serum 25-hydroxyvitamin D levels.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study

Matteo Lazzeroni et al.

Summary: This study suggests that low-dose tamoxifen significantly reduces the risk of recurrence in women with intraepithelial neoplasia (IEN) without additional adverse events. Even 7 years after treatment cessation, low-dose tamoxifen still effectively prevents recurrence from noninvasive breast cancer.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer

Ian H. H. Kunkler et al.

Summary: This study suggests that omission of radiotherapy in older women with low-risk, hormone receptor-positive early breast cancer may increase the risk of local recurrence, but has no detrimental effect on distant recurrence and overall survival.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Oncology

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

Andrea Eisen et al.

Summary: This article updates the recommendations of adjuvant bone-modifying agents in breast cancer treatment. Adjuvant bisphosphonate therapy should be discussed with all postmenopausal patients with primary breast cancer, regardless of hormone receptor status and human epidermal growth factor receptor 2 status. Adjuvant bisphosphonates are not substitutes for standard anticancer modalities and their benefits vary depending on the risk of recurrence. Factors influencing the decision to recommend adjuvant bisphosphonate use include patients' risk of recurrence, side effect risk, financial toxicity, drug availability, patient preferences, comorbidities, and life expectancy. Therapeutic options for preventing breast cancer recurrence include oral clodronate, oral ibandronate, and intravenous zoledronic acid. Early initiation of bisphosphonate therapy is recommended, and adjuvant denosumab is not recommended for preventing breast cancer recurrence.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Michael Gnant et al.

Summary: The addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor-positive breast cancer.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

P. Schmid et al.

Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) for Lymphedema Prevention after Axillary Lymph Node Dissection-A Single Institution Experience and Feasibility of Technique

Kelsey Lipman et al.

Summary: This study highlights the LYMPHA technique as a feasible and effective method for prevention of lymphedema. By performing lymphatic mapping and lymphaticovenous anastomosis during the primary surgery, the morbidity associated with lymphedema can be avoided. A retrospective review showed successful prevention of lymphedema with minimal surgical complications.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Oncology

Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

Walter Paul Weber et al.

Summary: The aim of this article is to discuss the demand for nipple-and skin-sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) and present clinical practice recommendations in the context of expanded indications for post-mastectomy radiation therapy (PMRT). The panel agrees that surgical technique for NSM/SSM should not be modified when PMRT is planned, with preference for autologous over implant-based BR. However, no specific recommendations are made regarding implant positioning, use of mesh or timing. The use of patient-reported outcomes in clinical practice is endorsed. The article emphasizes the importance of prospective randomized phase III studies and interdisciplinary collaboration for determining optimal sequencing and techniques for PMRT in the context of BR.

BREAST (2022)

Add to Collection

Article Oncology

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy

Vincent M. T. de Jong et al.

Summary: High sTILs (>= 75%) in young patients with chemotherapy-naive N0 TNBC indicate an excellent long-term prognosis, suggesting the consideration of sTILs in prospective clinical trials exploring (neo)adjuvant chemotherapy de-escalation strategies.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HP2-Early Breast Cancer

Ulrike A. Nitz et al.

Summary: The WSG-ADAPT-HR+/HER2- study demonstrates the feasibility of guiding systemic treatment for breast cancer using both the recurrence score (RS) and endocrine therapy (ET) response, and avoids the use of chemotherapy in pre- and postmenopausal patients with <= 3 involved lymph nodes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

C. E. Geyer et al.

Summary: The OlympiA trial demonstrated that adjuvant therapy with the oral PARP inhibitor, olaparib, significantly improves overall survival in patients with gBRCA1/2pv-associated early breast cancer. The study also showed improvements in invasive disease-free survival and distant disease-free survival, with no new safety issues identified.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

PIK3CA-mutations in breast cancer

Kristin Reinhardt et al.

Summary: This study investigated the prevalence of PIK3CA mutations in early stage breast cancer patients and their association with the course of disease. The results showed that PIK3CA mutations were more common in certain types of breast tumors, but did not have a significant association with recurrence-free interval overall. However, in specific subgroups of patients, such as those with hormone receptor-positive breast cancer receiving aromatase inhibitors, PIK3CA mutations were found to have a detrimental impact on prognosis.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Add to Collection

Article Oncology

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

H. J. Burstein et al.

Summary: The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, with over 3300 participants discussing key issues related to early breast cancer diagnosis and treatment. The conference emphasized customized recommendations for breast cancer treatment, highlighting the importance of individualized clinical features in patient care.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy

Ann H. Partridge et al.

Summary: The POSITIVE study aimed to investigate the impact of temporary interruption of adjuvant endocrine therapy for pregnancy in early breast cancer patients. Findings revealed that majority of patients were nulliparous women, with half of them opting for fertility preservation. Patients from different regions showed variations in disease characteristics and treatment choices.

BREAST (2021)

Add to Collection

Article Oncology

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

Icro Meattini et al.

LANCET ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

Michael Gnant et al.

Summary: This study showed that extending hormone therapy by 5 years in postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Stephen Johnston et al.

Summary: The combination of abemaciclib with an aromatase inhibitor showed significant clinical benefit in postmenopausal women with HR+, HER2- advanced breast cancer in the MONARCH 3 trial, leading to prolonged progression-free survival across all prognostic subgroups.

NPJ BREAST CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Adrian Murray Brunt et al.

LANCET (2020)

Add to Collection

Article Oncology

Knowledge gaps in oncoplastic breast surgery

Walter P Weber et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Stephen R. D. Johnston et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Breast cancer

Nadia Harbeck et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial

Irene L. Wapnir et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Sibylle Loibl et al.

LANCET ONCOLOGY (2018)

Add to Collection

Review Medicine, General & Internal

Breast cancer

Nadia Harbeck et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

Michael Gnant et al.

LANCET (2015)

Add to Collection

Article Medicine, General & Internal

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

R. Coleman et al.

LANCET (2015)

Add to Collection

Article Surgery

LyMPHA and the Prevention of Lymphatic Injuries: A Rationale for Early Microsurgical Intervention

Corrado Cesare Campisi et al.

JOURNAL OF RECONSTRUCTIVE MICROSURGERY (2014)

Add to Collection

Article Oncology

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

Mila Donker et al.

LANCET ONCOLOGY (2014)

Add to Collection

Editorial Material Medicine, General & Internal

Dual inhibition of HER2 in breast cancer treatment

Michael Gnant et al.

LANCET (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.